Data Bytes: Roche, Abbott pump up the volume on COVID-19 antigen tests
COVID-19 antigen test launches by Roche and Abbott are poised to dramatically raise the number of rapid, point-of-care tests available per month.
On Tuesday, Roche (SIX:ROG; OTCQX:RHHBY) announced the launch of its COVID-19 antigen test in countries that accept the CE mark, and said it plans to apply for emergency use authorization (EUA) by FDA. The pharma said 40 million tests per month would be available at launch, with capacity expected to grow more than twofold by year-end.
Abbott Laboratories (NYSE:ABT) announced it received EUA for its antigen test on Aug. 26. The company said it will ship “tens of millions of tests” in September, and ramp up to 50 million tests per month in October.
Quidel Corp. (NASDAQ:QDEL), Becton Dickinson and Co. (NYSE:BDX) and LumiraDx Ltd. — whose tests were granted EUA by FDA on May 8, July 2 and Aug. 18, respectively — each launched with production volumes of fewer than 10 million tests per month. LumiraDx plans to ramp up to 10 million tests per month by December.